Trillium appoints Biogen CSO to board
This article was originally published in Scrip
Executive Summary
Trillium Therapeutics, a Canadian biopharmaceutical company developing therapies for immune-mediated conditions, has appointed Dr Michael Gresser to its board of directors. Dr Gresser previously served as vice-president of research inflammation with Amgen, and was involved in the discovery of molecules for the products Singulair (montelukast) and the withdrawn anti-inflammatory Vioxx (rofecoxib). He is currently chief scientific officer of Oxford BioTherapeutics, a role he has held since late 2009.